HIV-1 Integrase Sequence Variability in Antiretroviral Naïve Patients and in Triple-Class Experienced Patients Subsequently Treated with Raltegravir
Autor: | Christina Trevino, W. Jeffrey Fessel, Robert W. Shafer, Vici Varghese, Paolo Libiran, Tommy F. Liu, Soo-Yon Rhee |
---|---|
Rok vydání: | 2010 |
Předmět: |
Anti-HIV Agents
Molecular Sequence Data Immunology Mutation Missense Integrase inhibitor HIV Infections HIV Integrase Drug resistance Biology Raltegravir Potassium Virology Genotype Genetic variation medicine Humans Amino Acid Sequence Genetic Variation Sequence Analysis DNA Sequence Notes Raltegravir biology.organism_classification Pyrrolidinones Integrase Regimen Infectious Diseases Amino Acid Substitution Lentivirus HIV-1 biology.protein medicine.drug |
Zdroj: | AIDS Research and Human Retroviruses. 26:1323-1326 |
ISSN: | 1931-8405 0889-2229 |
Popis: | Viruses were sequenced from 75 antiretroviral therapy (ARV)-naïve and from 75 ARV-treated patients who subsequently received a raltegravir-containing regimen. No major integrase inhibitor (INI)-resistance mutations were present in the 150 integrase (IN) sequences. Four ARV-naïve (5.3%) and two ARV-treated patients (2.7%) had one of the following minor INI-resistance mutations: L74M, E157Q, G163R, and R263K but there was no association between baseline raltegravir genotype and subsequent response to raltegravir treatment. We also combined our sequences with 4170 previously published group M IN sequences from INI-naïve patients to assess IN sequence variability and compared our findings with those of a study we performed in 2008 using data from 1563 patients. The number of polymorphic IN positions increased from 40% to 41% between the two studies. However, none of the major INI-resistance mutations was found to be polymorphic in either study and there were no significant changes in the prevalence of any of the minor INI-resistance mutations. |
Databáze: | OpenAIRE |
Externí odkaz: |